Shares of Ardelyx (NASDAQ: ARDX) surged 14.37% in pre-market trading on Friday, following the release of the company's impressive third-quarter 2025 financial results and an upward revision of its full-year guidance. The biopharmaceutical company's strong performance was primarily driven by robust sales growth of its lead product, IBSRELA.

Ardelyx reported total revenue of $110.3 million for Q3 2025, representing a significant 12.3% increase compared to the same period last year and beating analyst expectations of $100.878 million. The standout performer was IBSRELA, Ardelyx's treatment for irritable bowel syndrome with constipation (IBS-C), which generated $78.2 million in Q3 revenue, reflecting a remarkable 92% year-over-year growth. Based on this strong performance, the company raised its full-year 2025 revenue guidance for IBSRELA to between $270-275 million.

While the company reported a modest net loss of $969,000 for the quarter, investors appear to be focusing on the robust revenue growth and positive outlook. Additionally, Ardelyx announced progress on its pipeline, including the development of RDX10531, a next-generation NHE3 inhibitor with potential applications across multiple therapeutic areas. The company plans to file an Investigational New Drug (IND) application for RDX10531 in 2026, further bolstering its future prospects. This combination of strong current performance and promising pipeline developments has likely contributed to the significant stock price increase in pre-market trading.